A study testing whether a GLP-1 medicine, semaglutide, can help people lose weight.

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

• To be eligible for study participation, all subjects must meet all the following
• Medically healthy with no clinically significant medical history, vital sign, or coagulation results at Screening; chemistry, hematology, or urinalysis at Screening and Day -1 (SAD)/Day 0 (MD) as deemed by the Investigator
• Age 18 to 60 years, inclusive, at the time of Screening
• Body mass index ≥25 to \<35 kg/m2 if participating in the SAD phase or ≥27 to \<40 kg/m2 if participating in the MD phase, at the time of Screening
• Must be able to communicate well with the Investigator, understand and comply with the requirements of the study (including required confinement periods), and understand and provide written consent

Key exclusion criteria

• Any disorder which in the investigator's opinion might jeopardize the subject's safety, evaluation of results, or compliance with the protocol
• Any of the following obesity or glycemia-related history:
• Treatment with a GLP-1 receptor agonist within 90 days before screening
• Treatment with any medication for the indication of obesity within the past 90 days before screening
• A self-reported change in body weight \> 5 kg (11 lb) within 90 days before screening irrespective of medical records.